Sample Submission Guidelines Inquiry
Request a Quote

Pharmacometabolomics Services — Drug Metabolite and Metabolic Phenotype Profiling by LC-MS/MS

Pharmacometabolomics measures an individual's metabolic phenotype before and after drug administration to explain and predict how that individual responds to treatment. Applied to clinical and preclinical sample sets, it connects drug exposure, drug-derived metabolites, and endogenous pathway shifts inside a single analytical workflow — so the metabolic context of a response is measured, not assumed.

Two data layers from one sample set — parent drug and its metabolites alongside the endogenous metabolome

Pre-dose baseline metabolic profiles built for response and toxicity prediction modeling

Absolute quantification by scheduled MRM with isotope-labeled internal standards

High-resolution MS for unknown metabolite discovery and structural annotation

Method documentation formatted for direct use in a manuscript methods section

Pharmacometabolomics Service — Drug Metabolite and Endogenous Metabolic Phenotype Profiling by LC-MS/MS

What Pharmacometabolomics Measures

Pharmacometabolomics asks a question that pharmacokinetics alone cannot answer: given this individual's metabolic state before the first dose, how will this individual handle the drug? Two individuals can receive the same dose, reach similar plasma concentrations, and still diverge sharply in efficacy and toxicity. Metabolic capacity frequently accounts for the divergence: how much cofactor is available, how active the relevant enzymes are, how the gut microbiome processes the compound, and what competing substrates already occupy the same pathways.

Our pharmacometabolomics service profiles both sides of that relationship. Drug-related analytes tell you what the body did to the compound. Endogenous metabolites tell you what state the body was in when it did so. Reported together, they allow a study to move from "this subject responded differently" to a testable explanation grounded in measurable biochemistry — a level of resolution that supports patient stratification in later development.

This platform is used at the stage where mechanism matters: candidate profiling before candidate selection, preclinical safety interpretation, first-in-human study design, and translational work that needs to connect exposure, metabolic phenotype, and response in the same dataset. Related capabilities across the development timeline are covered in the metabolomics in drug development program, which follows the same analytes from candidate profiling through first-in-human study design.

Two Data Layers From One Sample Set

Pharmacometabolomics studies usually fail for a logistical reason rather than a scientific one: the drug data and the metabolomics data are generated by different laboratories, on different aliquots, with different internal standards. The two datasets then cannot be aligned at the sample level, and the correlation the study was designed to test becomes impossible to compute.

We extract once and acquire both layers from the same aliquot series, so every drug measurement and every endogenous metabolite measurement carry the same sample identifier and the same preparation history. Where metabolite identification has to go further than quantification, the same extracts feed drug metabolism analysis, which resolves the structures behind the measured concentrations.

Data Layer What We Quantify Analytical Approach Typical Output
Drug layer Parent drug and known metabolites — phase I oxidation and hydrolysis products, phase II glucuronide, sulfate, glycine, and glutathione conjugates; drug-derived analogs detected from high-resolution data Scheduled MRM on triple quadrupole for absolute quantification of the parent and targeted metabolites; data-independent acquisition on high-resolution MS for unknown or unexpected metabolites Concentrations per analyte per sample and per time point, with transition-level evidence for each reported metabolite
Endogenous layer Metabolic phenotype: amino acids and their derivatives, biogenic amines, acylcarnitines, organic acids, nucleotides and cofactors, bile acids, and lipids relevant to the drug's mechanism Targeted MRM panels for absolute quantification; untargeted high-resolution profiling for pathway-level coverage and differential analysis Absolute concentrations for panel analytes plus relative abundance and fold-change data for the untargeted set
Linked readout Baseline-versus-post-dose change, and the association between pre-dose metabolite levels and drug exposure or response markers Per-subject pairing across time points with multivariate modeling and pathway-level enrichment Response-association tables and pathway maps connecting the two layers at the subject level

Why the Baseline Metabolic Phenotype Predicts Drug Response

The information used for prediction is collected before the drug is given. A pre-dose sample already carries measurable signals that determine how a compound will be handled: the abundance of cofactors such as S-adenosylmethionine, folate species, and nicotinamide cofactors sets the ceiling on methylation, one-carbon transfer, and redox-dependent activation reactions. Amino acid and acylcarnitine profiles reflect mitochondrial and enzyme activity. Microbial metabolite patterns reflect a community that will chemically modify the compound before the host even absorbs it.

Because these signals are quantitative and stable within an individual over short intervals, they can be modeled against the response that follows. That is what makes the pre-dose sample the analytical center of a pharmacometabolomics study rather than a convenience control.

  • Enzyme and cofactor capacity — Cofactor pools and pathway intermediates constrain how much of a substrate can be converted, activated, or detoxified, which is why baseline profiles carry predictive weight that dose alone does not.
  • Microbial contribution — Gut bacteria metabolize drugs and produce metabolites that re-enter circulation. Capturing the microbial metabolite context requires the endogenous layer, not a drug panel.
  • Competing substrate load — Elevated endogenous substrates competing for the same enzymes change effective clearance. Baseline profiling exposes this competition before it appears as an unexplained outlier.
  • Nutritional and physiological state — Fasting status, diet-derived metabolites, and stress-related markers are all captured in the same acquisition, giving the modeling step a richer covariate set at no extra sample cost.

Analytical Platform — Scheduled MRM Combined With High-Resolution MS

Dual-Platform Strategy

Absolute quantification runs on a SCIEX QTRAP 6500+ triple quadrupole using scheduled MRM with two to three transitions per analyte and an isotope-labeled internal standard for every reported compound. Where a stable-isotope standard does not exist, the nearest structurally appropriate analog is used and the choice is stated in the report.

Unknown and unexpected metabolites are handled on a Thermo Scientific Q Exactive Orbitrap and an AB SCIEX TripleTOF 5600 using data-independent acquisition and MS/MS fragmentation. High-resolution accurate mass supports formula assignment, and neutral-loss and fragment-ion patterns support phase II conjugate assignment for glucuronide, sulfate, and glutathione products. Volatile and thermally stable analytes are covered by Agilent 7890B-5977A GC-MS, and chromatographic separation is developed on Waters ACQUITY and Agilent 1290 Infinity II UPLC systems.

The same extract also supports untargeted metabolomics, and analytes that need a number rather than a pattern are measured as targeted metabolomics panels against authentic standards.

Method Performance

Parameter Specification
Quantification Absolute, against authentic standards; 6- to 8-point calibration per analyte
Internal standards Isotope-labeled standard spiked at the earliest preparation step for every reported analyte
Calibration Matrix-matched where matrix effects are significant; weighted regression to fit the working range
Precision Intra-batch below 10 percent for the majority of analytes; inter-batch within 15 percent
Recovery window Internal standard recovery monitored per sample, typically within 80 to 120 percent
Calibration quality R² at or above 0.99 for reported analytes, with back-calculated accuracy documented
QC design Pooled QC injections bracketing each batch, plus blank and extraction-blank monitoring for carryover

Pharmacometabolomics Workflow

1

Study Design and Sample Set Planning

  • Review the dosing schedule, the response or toxicity endpoint, and the number of subjects or animals available
  • Define which time points pair with the pre-dose baseline for the association model
  • Fix the analyte list for the drug layer and the endogenous layer before extraction is scheduled
2

Sample Preparation With Isotope-Labeled Internal Standards

  • Internal standard cocktail spiked at homogenization or protein precipitation, before any analyte can be lost
  • Matrix-specific extraction: precipitation for plasma and serum, liquid-liquid extraction for lipophilic analytes, enzymatic deconjugation where phase II conjugates must be measured as aglycone equivalents
  • Pre-dose and post-dose samples from the same subject extracted in the same batch to remove batch effects from the paired comparison
3

Dual-Platform Acquisition

Scheduled MRM on the QTRAP 6500+ for absolute quantification of the drug layer and the targeted endogenous panel, two to three transitions per analyte. The same extract is then acquired by data-independent high-resolution MS on the Orbitrap and TripleTOF 5600 platforms for unknown metabolite detection and structural annotation. Sequence order is fixed: blank, calibration curve, matrix-matched QC, randomized study samples with QC injections at intervals, closing QC.

4

Quantification, QC, and Data Review

Calibration curves are fitted with weighted regression and evaluated on back-calculated accuracy. Internal standard recovery, pooled QC dispersion, blank carryover, and retention-time stability are reviewed per analyte. Analytes failing the acceptance window are flagged in the report rather than silently dropped, so the reviewer can see the boundary of what the data supports.

5

Statistical Modeling and Pathway Annotation

Pre-dose metabolite levels are modeled against post-dose exposure and response endpoints; within-subject change is computed for every paired time point. Differential analytes are annotated to KEGG and HMDB identifiers and mapped onto pathways so that the statistical result can be interpreted mechanistically instead of reported as a ranked compound list.

Pharmacometabolomics workflow — five-step pipeline from study design through dual-platform acquisition to response association modeling

Sample Requirements for Clinical and Preclinical Samples

Sample Type Amount Required Preparation Instructions Storage and Shipping
Plasma / Serum ≥ 50 µL Collect in EDTA or heparin tube, centrifuge, aliquot supernatant, avoid hemolysis Store at −80°C; ship on dry ice
Whole Blood / DBS ≥ 20 µL Dried blood spot cards dried completely before packing, or whole blood aliquoted directly Store at −80°C; ship on dry ice
Urine ≥ 50 µL Centrifuge to remove debris, record collection interval, aliquot Store at −80°C; ship on dry ice
Tissue (liver, kidney, brain) 10–50 mg Snap freeze in liquid nitrogen immediately after collection; record wet weight before freezing where possible Store at −80°C; ship on dry ice
Feces ≥ 20 mg Aliquot promptly, avoid repeated thawing; relevant where microbial drug metabolism is part of the question Store at −80°C; ship on dry ice
Bile ≥ 50 µL Collect on ice, centrifuge, aliquot supernatant Store at −80°C; ship on dry ice
Cell Pellets ≥ 1 × 106 cells Wash with cold PBS, centrifuge, remove supernatant, freeze the pellet Store at −80°C; ship on dry ice
Cell Culture Medium ≥ 100 µL Centrifuge, collect supernatant, record time from dosing to collection Store at −80°C; ship on dry ice

Notes

  • Pre-dose and post-dose samples from the same subject must be submitted together so they can be extracted in one batch
  • Record the time from dosing to collection for every post-dose sample; the association model depends on it
  • Avoid repeated freeze-thaw cycles; split clinical samples into single-use aliquots before the first freeze
  • Label each tube with subject ID, time point, matrix type, and collection date, and submit a matching sample list
  • Contact us before shipping low-volume pediatric or microdialysis samples so that extraction can be scaled to the available volume

Deliverables — What You Receive

  • Quantitative concentration tables — Absolute concentrations for every reported analyte, per sample and per time point, in Excel and CSV. Drug-layer and endogenous-layer analytes are delivered in linked tables sharing one sample identifier.
  • QC and calibration report — Calibration curves with regression parameters and back-calculated accuracy, internal standard recovery per sample, pooled QC dispersion, blank carryover, and retention-time stability for each analyte.
  • Chromatograms and high-resolution data — MRM traces for quantified analytes, plus MS/MS spectra and accurate mass data supporting the identity of every metabolite reported from the drug layer.
  • Response-association analysis — Paired pre-dose versus post-dose comparisons at the subject level, and the association between baseline metabolite levels and the exposure or response endpoints agreed at study design.
  • Pathway annotation — Differential metabolites annotated to KEGG and HMDB identifiers and mapped to pathways, delivered as tables and as publication-ready figures.
  • Methods documentation — Sample preparation protocol, chromatographic and MS parameters, MRM transitions, internal standard assignments, and data-processing settings, written so that a methods section can be assembled from it directly.

Representative Data

Scheduled MRM chromatogram of a parent drug and its phase II metabolites with isotope-labeled internal standard overlay

Scheduled MRM trace for a parent drug and two phase II conjugates, with the isotope-labeled internal standard co-eluting in the same transition window.

Matrix-matched calibration curve for a drug metabolite with weighted regression and LLOQ marked

Matrix-matched calibration curve across six concentration levels with weighted regression and the lower limit of quantification marked.

Pooled QC dispersion and internal standard recovery across a pharmacometabolomics batch

Pooled QC dispersion per analyte and internal standard recovery per sample across a full acquisition batch.

Baseline metabolite levels stratified by response group with pathway map showing drug-associated metabolic shifts

Pre-dose metabolite levels stratified by post-dose response group, with a pathway map of the drug-associated metabolic shifts.

Applications of Pharmacometabolomics

Preclinical Safety Interpretation

Determine whether an observed toxicity is accompanied by a specific metabolic perturbation, and whether the perturbation precedes or follows the histological finding. A dedicated readout for that question is provided by drug toxicity assessment, which pairs the metabolic finding with the dose and exposure data.

First-in-Human Response Stratification

Use pre-dose metabolic profiles to separate responders from non-responders in early cohorts, and to identify the metabolic features that carry the separation.

Exposure and Metabolism Alignment

Quantify the parent drug and its metabolites alongside pathway intermediates to connect exposure with the metabolic route actually taken.

Multi-Component and Herbal Exposure Tracking

Track several co-administered compounds and their transformation products in the same acquisition, suited to multi-herb formulations where exposure is otherwise unmeasurable.

Pharmacodynamic Biomarker Discovery

Identify endogenous metabolites that track the pharmacological effect rather than the drug concentration, providing readouts closer to the mechanism of action. Candidates can then be carried forward into biomarker metabolomics validation.

Lipid Remodeling That Accompanies Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia


Journal: Clinical and Translational Medicine

Published: 2022

DOI: https://doi.org/10.1002/ctm2.1146


Background

Chronic myeloid leukemia is treated with tyrosine kinase inhibitors directed at BCR::ABL1, and most patients reach a durable response. The outstanding clinical problem is resistance, and the usual explanation is a mutation in the BCR::ABL1 kinase domain. A subset of resistant patients carries no such mutation, which leaves the resistance phenotype without a molecular cause and without a readout that can be measured directly from the cells.

The challenge was to determine whether the metabolic state of resistant leukemic cells differs measurably from that of sensitive cells, and to establish that the difference sits on a lipid route rather than on the gene's known function in lipid storage. Two clinical settings had to be covered at once: resistance arising without a kinase domain mutation, and progression from chronic phase to blast phase.


Findings (from the published study)

  • G0S2 (G0/G1 switch gene 2) was downregulated in three independent settings of tyrosine kinase inhibitor resistance: BCR::ABL1 kinase-independent resistance, progression from chronic phase to blast phase, and chronic myeloid leukemia against normal myeloid progenitors.
  • The loss was traced to regulation rather than mutation. MYC/MAX occupancy at the G0S2 promoter together with promoter CpG methylation repressed transcription of the gene.
  • Untargeted LC-MS lipidomics compared K562 cells carrying a non-targeting control, a G0S2 short hairpin RNA, or ectopic G0S2. The lipidomics acquisition and lipid annotation were performed at Creative Proteomics.
  • G0S2 knockdown reduced very long-chain diacylglycerol and triacylglycerol species, while ectopic G0S2 increased triacylglycerol together with membrane lipids — phosphatidylcholine (PC) and phosphatidylethanolamine (PE) species accumulated.
  • The largest single lipid difference between ectopic G0S2 and G0S2 knockdown was PA(22:6_22:1)-H, 3.2-fold higher in the cells expressing ectopic G0S2.
  • KEGG enrichment placed the affected routes in glycerophospholipid metabolism, with autophagy, glycosylphosphatidylinositol-anchor biosynthesis, ferroptosis, and choline metabolism in cancer also altered — a set consistent with membrane lipid remodeling rather than with storage alone.
  • The lipid phenotype was separable from the established function of G0S2 as an inhibitor of adipose triglyceride lipase: G0S2 knockdown and ATGL knockdown gave different transcriptional profiles, so the survival effect did not reduce to a change in lipolysis.

Untargeted LC-MS lipidomics of K562 cells with G0S2 knockdown or ectopic G0S2, showing reduced very long-chain di- and triglycerides and increased phosphatidylcholine and phosphatidylethanolamine species, with KEGG lipid pathway enrichmentFigure 7. Very long-chain di- and triglycerides fall with G0S2 knockdown, while ectopic G0S2 raises triglycerides and membrane phospholipids.

Proposed model of G0S2 tumor suppressor activity in chronic myeloid leukemia, acting on triacylglyceride accumulation through adipose triglyceride lipase inhibition and lysophosphatidic acid acyltransferase activityFigure 8. Model linking G0S2 to triglyceride and membrane lipid homeostasis in chronic myeloid leukemia.

Process Insight

The part of this study that matters analytically is the separation between lipid storage and lipid remodeling. Triacylglycerol increased with ectopic G0S2, which on its own would read as a storage effect, but phosphatidylcholine and phosphatidylethanolamine species increased with it and phosphatidic acid was the largest single change. Storage pools and membrane pools move for different reasons, and telling them apart requires species-level resolution: chain length, degree of unsaturation, and head group each have to be reported separately rather than collapsed into a total lipid content value. The parallel ATGL knockdown arm is what made that distinction testable.

Where Our Pharmacometabolomics Service Fits

Creative Proteomics performed the lipidomics acquisition in this study, and the same principles apply to our pharmacometabolomics programs:

  • Species-level lipid resolution — chain length, unsaturation, and head group are reported per lipid species, which is what distinguishes a storage pool change from a membrane remodeling change instead of reporting both as one lipid content value.
  • Drug-response arms extracted and acquired together — control, knockdown, and overexpression arms are processed in the same batch with internal standards, so a difference between arms reflects the perturbation rather than the extraction order.
  • Interpretation delivered at pathway level — differential lipid species are annotated and mapped to pathways such as glycerophospholipid metabolism, so the phenotype is handed back in a form that can be tested against a pharmacological question.
  • Primary data retained for re-analysis — the acquired spectra stay searchable after the first report, which matters when the same samples later need to be re-queried for a different lipid class.

Reference

  1. Gonzalez, M.A., Olivas, I.M., Bencomo-Alvarez, A.E. et al. Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukemia (CML) by disrupting glycerophospholipid metabolism. Clinical and Translational Medicine 12(12), e1146 (2022).

Frequently Asked Questions

How is pharmacometabolomics different from a standard drug metabolism study?

A drug metabolism study answers what the body did to the compound — which metabolites formed, through which routes, and at what concentrations. Pharmacometabolomics adds the other direction of the relationship: what state the body was in, and how that state influenced the response. Practically, that means the same acquisition also covers the endogenous metabolome, and the analysis includes pre-dose baseline levels as variables rather than treating them as background. Both layers are required; a drug-only dataset cannot support a response-prediction question.

Can you quantify the parent drug and its metabolites in the same run as endogenous metabolites?

Yes. Scheduled MRM acquisition is not limited to one compound class, so the drug layer and the targeted endogenous panel are quantified in a single method with transitions for each analyte. Extraction conditions have to satisfy both sets of analytes, which we resolve during method setup: plasma and serum work well with precipitation, while lipophilic drug metabolites may require liquid-liquid extraction that we then validate for the endogenous analytes being reported. Because both layers come from the same extract, the concentrations are directly comparable at the sample level.

Do you report absolute concentrations or relative abundances?

Both, and the report distinguishes them clearly. Analytes with authentic standards are quantified absolutely against a calibration curve, with isotope-labeled internal standards spiked at the earliest step. Compounds covered only by the high-resolution untargeted acquisition are reported as relative abundance with fold-change and statistical significance. Each table states which type of value it contains, so a reader is never left guessing whether a number is a concentration or a normalized signal.

How does the analysis handle metabolites that are not on the original target list?

This is the reason high-resolution data is acquired and retained for every sample. Data-independent acquisition on the Orbitrap and TripleTOF platforms captures fragment information across the full mass range, so when a metabolite or a drug-derived analog turns out to matter, it can be searched retrospectively against spectral libraries and confirmed against a standard if one is available. Nothing on the original target list limits what can be recovered later, provided the fragment data were acquired and a reference is available for confirmation.

How many subjects or samples do I need for the baseline analysis to be meaningful?

It depends on the size of the effect you are trying to detect, but the practical floor for a pharmacometabolomics association analysis is usually in the range of 20 to 30 subjects with paired pre-dose and post-dose samples. Below that, the analysis remains descriptive and we will say so in the report rather than fitting a model the data cannot support. Sample volume is rarely the limiting factor: most plasma and serum analytes are covered from 50 µL, and urine, feces, and tissue work at similar scale.

Can you build a custom method for a compound that is not in your catalog?

Yes. Custom method development starts with a feasibility check against our compound library and available standards, then moves to optimization of MRM transitions, chromatographic conditions, and extraction for the matrix you are working with. The method is then evaluated for linearity, precision, recovery, and matrix effects before study samples are analyzed. Because this development work runs before sample analysis begins, custom compounds should be raised with us during study design rather than after samples arrive.

What documentation do you provide for a manuscript methods section?

The report includes the extraction protocol with reagent compositions, chromatographic gradient and column details, MS source parameters, MRM transitions for each analyte, internal standard assignments, calibration and regression settings, and the software versions used for processing. QC results — calibration accuracy, internal standard recovery, pooled QC dispersion, carryover, and retention-time stability — are reported per analyte so that the data-quality statement in a manuscript can be written from the report itself.

Sample Report

Want to See a Sample Metabolomics Report?

Review a representative report to see how sample information, analytical methods, and results are documented.

Illustrative preview of blurred metabolomics report pages with sample details, analytical methods, and results

Request a Demo Report

Complete the form below to request a sample report. Our team will follow up by email.

Select the service most relevant to your request.
For Research Use Only. Not for use in diagnostic procedures.
inquiry

Get Your Custom Quote

Connect with Creative Proteomics Contact Us Contact Us
return-top